Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- TDA RESEARCH, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- MK5ANJVWVZK7
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
A newly discovered class of nanoscale materials, the metal-carbon nanoencapsulates,
has considerable potential to improve on current molecular-based MRI contrast
enhancing agents. Metal-carbon nanoencapsulates are 2 nm diameter and larger
particles in which graphitic carbon layers encase single crystals of metals or metal
carbides. Their continuous graphitic carbon shells are several layers thick and highly
stable. This shell protects the metal nanocrystal from oxygen and water, prevents the
metal from leaving the encapsulate, allows magnetic interactions between the metal
and exterior molecules, and provides a scaffolding for chemical derivitization. These
physical characteristics impart significant advantages to metal-carbon
nanoencapsulates and will result in a safer, more effective class of novel MRI
contrast enhancing agents based on metal-carbon nanoencapsulates. The
nanoencapsulates will be aminated, allowing for solubilization and coupling
reactions on the surface of the nanoencapsulate. The relaxivity characterisitics of
gadolinium containing solubilized nanoencapsulates with be evaluated, and the
covalent conjugation of proteins will be tested. Potential applications for these
nanoencapsulate contrast agents include imaging of the blood pool, RES, cancerous
lesions, and targeted imaging of receptors and gene expression.
PROPOSED COMMERCIAL APPLICATION:
The development of a new class of potent MRI contrast enhancing agents based on
magnetic metal-carbon nanoencapsulates with higher stabilities, higher relaxivities,
lower required in vivo concentrations and novel utility in target-specific imaging
applications will have substantial commercial impact. Once fully developed, these
safer and more powerful contrast enhancing agents will be in demand for clinical use
in MRI laboratories and hospitals around the country in applications like MR
angiography, imaging of reticuloendothelial system components, imaging of
cancerous lesions with targeted agents, and for imaging gene expression and other
receptors.
Technology keywords
Not reported
Research funding history
951 SBIR/STTR records share this UEI (1988–2026). Reported award amounts total $317,960,224. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Defense, Department of Energy, National Aeronautics and Space Administration, Environmental Protection Agency, National Science Foundation, Department of Health and Human Services
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards